Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2025-12-24 @ 7:24 PM
NCT ID:
NCT02110303
Eligibility Criteria:
Inclusion Criteria:
* Patients aged ≥40 years with angiographically proven multivessel coronary artery disease defined as at least two major epicardial vessels with any combination of either (a) \>50% luminal stenosis, or (b) previous revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).
* Provision of informed consent prior to any study specific procedures
Exclusion Criteria:
* An acute coronary syndrome within the last 12 months
* An indication for dual anti-platelet therapy, such as drug eluting stent
* Inability to take aspirin
* Receiving thienopyridine therapy such as clopidogrel or prasugrel
* Percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 months
* Inability or unwilling to give informed consent
* Woman with child-bearing potential and who are breastfeeding will not be enrolled into the trial (woman who have experienced menarche, are pre-menopausal, have not been sterilised or who are currently pregnant)
* Known hypersensitivity to ticagrelor or one of its excipients
* Active pathological bleeding or bleeding diathesis
* Significant thrombocytopenia: \<100 x 10\^9 /L
* History of intracranial haemorrhage
* Moderate to severe liver impairment (Child's Grade B or C)
* Maintenance therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors, such as ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin
* Major intercurrent illness or life expectancy \<1 year
* Renal dysfunction (eGFR ≤30 mL/min/1.73 m2)
* Contraindication to iodinated contrast agents
* Planned coronary revascularization or major non-cardiac surgery in the next 12 months
* Maintenance therapy with simvastatin at doses greater than 40mg daily
* Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT02110303
Study Brief:
Protocol Section:
NCT02110303